Chondroitin sulfate is a naturally occurring substance in the body. It is a major constituent of cartilage—the tough, elastic connective tissue found in the joints.
Based on the evidence of preliminary double-blind studies, chondroitin is widely used as a treatment for osteoarthritis, the typical arthritis that many people suffer as they get older. However, the supporting evidence for this use is weak.
There is some evidence that chondroitin might go beyond treating symptoms and actually protect joints from damage. Current medical treatments for osteoarthritis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), treat the symptoms but don't actually slow the disease's progression, and they may actually make it get worse faster.1-5 Chondroitin (along with glucosamine) may take the treatment of osteoarthritis to a new level. However, more research needs to be performed to prove definitively that this exciting possibility is real.
Chondroitin is not an essential nutrient. Animal cartilage is the only dietary source of chondroitin. (When it's on your plate, animal cartilage is called gristle.) Unless you enjoy chewing gristle, you'd do best to obtain chondroitin in pill form from a health food store or pharmacy.
The usual dosage of chondroitin is 400 mg taken 3 times daily, indefinitely. Two studies (mentioned below) used an "on and off" schedule of chondroitin (taking it for 3 months, going off of it for 3 months, and then taking it again). Other studies involved taking chondroitin daily. Regardless of which way you use it, be patient! The results are thought to take weeks to develop.
There are large differences between chondroitin products based on their chemical structure.8 This can be expected to lead to significant differences in absorption and hence effectiveness. Most likely, chondroitin products with physically smaller molecules (fewer than 16,900 daltons) are better absorbed. In addition, a review conducted in 2003 by the respected testing organization, Consumerlab.com, found that some products sold as providing chondroitin actually contained far less chondroitin (or even none at all) than stated on the label.39 It may be advisable to use the exact products that were tested in double-blind trials.
Numerous double-blind studies have found evidence that chondroitin can relieve the symptoms of osteoarthritis and possibly also slow the progression of the disease.9-16 However, most of these studies suffer from serious problems in design, statistical analysis, and reporting. When pooled together, the results of the three best studies failed to demonstrate benefit.43 On balance, the evidence for chondroitin’s effectiveness for osteoarthritis is inconsistent and incomplete.45,46
Chondroitin has also been proposed as a treatment for other conditions, such as atherosclerosis, interstitial cystitis, and high cholesterol, but as yet the evidence that the supplement might help is far too weak to rely upon at all.17-18,40
For years, experts stated that oral chondroitin couldn't possibly work because its molecules are so big that it seemed doubtful that they could be absorbed through the digestive tract. However, in 1995, researchers laid this objection to rest when they found evidence that up to 15% of chondroitin is absorbed intact.19
Many but not all double-blind, placebo-controlled studies indicate that chondroitin can relieve symptoms of osteoarthritis.
For example, one study enrolled 85 people with osteoarthritis of the knee and followed them for 6 months.9 Participants received either 400 mg of chondroitin sulfate twice daily or placebo. At the end of the trial, doctors rated the improvement as good or very good in 69% of those taking chondroitin sulfate, but in only 32% of those taking placebo.
Another way of comparing the results is to look at maximum walking speed among participants. Whereas individuals in the chondroitin group were able to improve their walking speed gradually over the course of the trial, walking speed did not improve at all in the placebo group. Additionally, there were improvements in other measures of osteoarthritis, such as pain level, with benefits seen as early as 1 month. This suggests that chondroitin was able to stop the arthritis from gradually getting worse. (See also Slowing the Progression of Osteoarthritis.)
In two of these studies, chondroitin was taken for two separate 3-month periods separated by 3 months of no treatment;10,37 in the others, it was taken continuously. No comparison of these two ways of using chondroitin has been published.
Benefits were also seen in two other double-blind, placebo-controlled trials involving a total of more than 350 individuals.12,13,15
Another double-blind study compared chondroitin to the anti-inflammatory drug diclofenac and found equivalent benefits.16
Additional studies combined glucosamine with chondroitin. A 6-month, double-blind, placebo-controlled study of 93 people with knee arthritis found that a combination of glucosamine and chondroitin (along with manganese) was more effective than placebo.14 Another double-blind, placebo-controlled study evaluated chondroitin/glucosamine for temporomandibular joint disease (TMJ) but found equivocal results.20
However, a very large (1,583 participants) and well-designed study failed to find either chondroitin or glucosamine plus chondroitin more effective than placebo.42 When this study is pooled together with the two other best designed trials, no overall benefit is seen.43 Yet another study also failed to find benefit with glucosamine plus chondroitin.44 And finally, in a systematic review including 10 randomized trials involving 3,803 patients with osteoarthritis of hip or knee, researchers found that chondroitin alone or with glucosamine did not improve pain.46
It has been suggested that chondroitin, like glucosamine, may primarily appear effective in studies funded by manufacturers of chondroitin products.
Osteoarthritis tends to worsen with time. As mentioned earlier, no conventional treatment for osteoarthritis protects joints from progressive damage. Some evidence hints that chondroitin can do this, but it is too early to consider the matter settled.38
One study examined the progression of osteoarthritis in 119 people for 3 years.22 In this double-blind, placebo-controlled trial, those who took 1,200 mg of chondroitin daily showed lower rates of severe joint damage. Only 8.8% of the chondroitin group developed severely damaged joints during the 3 years of the study, compared with almost 30% of the placebo group. This suggests that chondroitin was slowing the progression of osteoarthritis.
Protective effects were also seen in three 1-year studies enrolling a total of more than 200 people.10,11,37
Animal studies provide some additional evidence for a joint-protecting benefit.23 However, as with studies of chondroitin for treating osteoarthritis, too high a proportion of the research record involving prevention of osteoarthritis has involved industry-funded research.
Scientists are unsure how chondroitin sulfate works (if indeed it does).
At its most basic level, chondroitin may help cartilage by providing it with the building blocks it needs to repair itself. Chondroitin is also believed to block enzymes that break down cartilage in the joints.23,24 Another theory holds that chondroitin increases the amount of hyaluronic acid in the joints.25 Hyaluronic acid is a protective fluid that keeps the joints lubricated. Finally, chondroitin may have a mild anti-inflammatory effect.24
Chondroitin generally does not cause much in the way of side effects, besides occasional mild digestive distress. However, there is one case report of an exacerbation of asthma caused by use of a glucosamine-chondroitin product.26 In addition, there are theoretical concerns that chondroitin might have a mild blood-thinning effect, based on its chemical similarity to the anticoagulant drug heparin. Reassuringly, there are no case reports of any problems relating to this, and studies suggest that chondroitin has at most a mild anticoagulant effect.27 Nonetheless, prudence suggests that, based on these findings, chondroitin should not be combined with blood-thinning drugs, such as warfarin (Coumadin), heparin, and aspirin, except under physician supervision. In addition, individuals with bleeding problems, such as hemophilia, or who are temporarily at risk for bleeding (for example, undergoing surgery or labor and delivery) should avoid chondroitin.
1. Brandt KD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med. 1987;83:29-34.
2. Brooks PM, Potter SR, Buchanan WW. NSAID and osteoarthritis—help or hindrance [editorial]. J Rheumatol. 1982;9:3-5.
3. Shield MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm. 1993;13:7-16.
4. Palmoski MJ, Brandt KD. Effects of some nonsteroidal antiinflammatory drugs on proteoglycan metabolism and organization in canine articular cartilage. Arthritis Rheum. 1980;23:1010-1020.
5. Rashad S, Revell P, Hemingway A, et al. Effect of nonsteroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989;2:519-522.
6. Lippiello L, Woodward J, Karpman R, et al. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop. 2000;(381):229-240.
7. Lippiello L, Karpman RR, Hammad T. Synergistic effect of glucosamine HCL and chondroitin sulfate on in vitro proteoglycan synthesis by bovine chondrocytes. Presented at: American Academy of Orthopaedic Surgeons 67th Annual Meeting; March 15-19, 2000.
8. Adebowale AO, Cox DS, Liang Z, et al. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. J Am Nutraceutical Assoc. 2000;3:37-44.
9. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998;6(suppl A):31-36.
10. Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6) [translated from French]. Presse Med. 1998;27:1862-1865.
11. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998;6(suppl A):39-46.
12. Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998;6(suppl A):25-30.
13. Mazieres B, Loyau G, Menkes CJ, et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo [in French; English abstract]. Rev Rhum Mal Osteoartic. 1992;59:466-472.
14. Das A Jr, Hammad TA. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage. 2000;8:343-350.
15. L'Hirondel JL. Double-blind clinical study with oral administration of chondroitin sulphate versus placebo in tibiofemoral gonarthrosis (125 patients) [in German]. Litera Rheumatol. 1992;14:77-84.
16. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23:1385-1391.
17. Nakazawa K. Effect of chondroitin sulfates on atherosclerosis. I. Long term oral administration of chondroitin sulfates to atherosclerotic subjects [in Japanese]. Nippon Naika Gakkai Zasshi. 1970;59:1084-1092.
18. Nakazawa K, Murata K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. ZFA. 1979;34:153-159.
19. Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995;45:918-925.
20. Nguyen P, Mohamed SE, Gardiner D, et al. A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio. 2001;19:130-139.
21. Cohen M, Wolfe R, Mai T, et al. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol. 2003;30:523-528.
22. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 1998;6(suppl A):37-38.
23. Uebelhart D, Thonar EJ, Zhang J, et al. Protective effect of exogenous chondroitin 4, 6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998;6(suppl A):6-13.
24. Ronca F, Palmieri L, Panicucci P, et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6(suppl A):14-21.
25. Hungerford DS. Treating osteoarthritis with chondroprotective agents. Orthopedic Special Edition. 1998;4:39-42.
26. Tallia AF, Cardone DA. Asthma exacerbation associated with glucosamine-chondroitin supplement. J Am Board Fam Pract. 2002;15:481-484.
27. Abdel Fattah W, Hammad T. Chondroitin sulfate and glucosamine: A review of their safety profile. JANA. 2001;3:16-23.
28. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998;6(suppl A):39-46.
29. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 1998;6(suppl A):37-38.
30. Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6) [translated from French]. Presse Med. 1998;27:1862-1865.
31. Uebelhart D, Thonar EJ, Zhang J, et al. Protective effect of exogenous chondroitin 4, 6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998;6(suppl A):6-13.
32. Uebelhart D, Thonar EJ, Zhang J, et al. Protective effect of exogenous chondroitin 4, 6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998;6(suppl A):6-13.
33. Ronca F, Palmieri L, Panicucci P, et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6(suppl A):14-21.
34. Hungerford DS. Treating osteoarthritis with chondroprotective agents. Orthopedic Special Edition. 1998;4:39-42.
35. Ronca F, Palmieri L, Panicucci P, et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6(suppl A):14-21.
36. Abdel Fattah W, Hammad T. Chondroitin sulfate and glucosamine: a review of their safety profile. JANA. 2001;3:16-23.
37. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004;12:269-276.
38. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163:1514-1522.
40. Palylyk-Colwell E. Chondroitin sulfate for interstitial cystitis. Issues Emerg Health Technol. 2006;84:1-4.
41. Braun WA, Flynn MG, Armstrong WJ, et al. The effects of chondroitin sulfate supplementation on indices of muscle damage induced by eccentric arm exercise. J Sports Med Phys Fitness. 2006;45:553-60.
42. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808.
43. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146:580-590.
44. Messier SP, Mihalko S, Loeser RF, et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage. 2007 Jun 8. [Epub ahead of print]
45. Monfort J, Martel-Pelletier J, Pelletier JP. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of metaanalyses. Curr Med Res Opin. 2008 Apr 15.
46. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
Last reviewed December 2015 by EBSCO CAM Review Board Last Updated: 12/15/2015